Ketek's new labeling approved by FDA

Share this article:
Ketek (telithromycin), Sanofi-Aventis' antibiotic, has had new labeling approved by the FDA, including a bolded warning and additional information on liver toxicity and failure, as well as revised recommendations for use in patients with myasthenia gravis. The agency says Ketek's benefits outweigh its potential risks when used according to the labeling.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.